First, retatrutide is investigational
The overlapping side effects and cardiovascular concerns
This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States. Noom reports strong early outcomes with microdosing strategy This gradual approach referenced by Egler is Nooms low and slow titration approach with microdoses, which are considered fractions of the standard medication doses, 25% or less
By week 36, this weight loss effect was even more pronounced, increasing from 9.4% to 14.7%, while the placebo group saw a reduction of only 2.3%
What Factors Affect These Results
1): (1) initial consultations with a doctor and health coach (dietitian and/or fitness coach) to determine weight loss and health goals, assess suitability for GLP-1 RA, record baseline measurements, and personalize a lifestyle intervention plan
